ACT EU trial-advice pilot goes permanent in January 2027, with a final report due first

What happened

Slovakia's medicines agency ŠÚKL has announced that the ACT EU pre-submission advice pilot for clinical trials will continue as a permanent initiative from January 2027. The scheme is an EU-level advisory route for sponsors who are preparing clinical trial applications. According to ŠÚKL, a final report covering about 30 applications is due by the end of 2026.

The announcement is short on operating detail. The record does not say how sponsors apply, which trial types qualify, how many requests the permanent scheme can take, or what the advice is binding on. It also does not say what the final report will measure. Teams should treat those points as unknown until the EU-level partners publish more.

Why the move to permanent status matters

A pilot is a trial run, and sponsors have understandably treated it as one: a limited experiment that is hard to build into a development plan. Permanent status changes that. Sponsors can start to plan pre-submission advice as a routine step in EU trial preparation instead of an opportunity that might lapse.

The sequence is also worth noting. The final report on roughly 30 applications is due before the permanent scheme starts. If it is published, it will be the first evidence of how the advice worked in practice. The record does not say whether it will be public or what it will contain, so the report is something to watch for and not yet something to plan around.

About 30 applications is a small sample. Any conclusions drawn from it should be read with that in mind, and the records say nothing about how the sample was chosen or what outcomes were tracked.

Regulatory context: more procedural clarity at the front end

Two other items from the past week point the same way, though neither concerns the pilot directly. On 28 October EMA published a notice to sponsors on validating and qualifying computerised systems used in clinical trials. The information available does not set out the notice's details, so its practical requirements cannot yet be assessed. It still shows the EU regulator giving sponsors written expectations on a topic that often causes inspection findings.

In a separate area, Austria's BASG reports that the CMDh has revised its validation advice for mutual recognition and decentralised procedures. It has updated the request templates used by reference member states and flagged which national requirements actually block the start of a procedure. In particular, the reference member state can start a procedure when concerned member states fail to answer validation queries. That is a marketing authorisation process, not a clinical trial one, and the two should not be conflated. But it reflects the same broader pattern: regulators are trying to remove avoidable friction at the start of a procedure.

Pre-submission advice fits that pattern. Questions about a trial application are cheaper to resolve before submission than during validation or assessment. The records do not show whether the ACT EU scheme has done this in practice, which is why the final report matters.

Who is affected

The most direct audience is sponsors preparing EU clinical trial applications, especially those planning multinational submissions in which they want early alignment on the application package. Regulatory affairs and clinical operations leads should find out how the permanent scheme will be accessed so they can budget time for it in start-up timelines.

Sponsors with parallel US plans face a different pathway. Processa Pharmaceuticals, for example, announced FDA IND clearance for a Phase 2 trial of its oral BTK inhibitor VT-7208 in urticaria. The US IND process and EU trial applications are separate routes, and the records do not compare their timelines or outcomes. For global programmes, the practical point is that the EU advice scheme is one more regional touchpoint to sequence alongside the US process, not a substitute for it.

Quality and IT teams are affected indirectly. The EMA notice on computerised systems suggests that systems validation will be a topic whenever sponsors prepare for EU trials. Whether pre-submission advice will cover it is not stated in the records.

What to watch

The first item is the final report due by the end of 2026. Check whether it is published and what it says about the types of applications covered and the questions raised. The second is the operating detail for January 2027: application mechanics, eligibility and capacity. The third is the content of the EMA computerised systems notice, which sponsors should read in full against their own validation practices rather than rely on summaries.

Until those details arrive, the sound approach is modest: keep the scheme in view, do not assume it will shorten any timeline, and keep national and EU-level contacts informed of the programme.